Introduce Lunstgen Parvec in Ear(s), Perc, New Tech 11

This code describes the administration of DB-OTO, a novel therapeutic agent, directly into the cochlea of one or both ears. The infusion is performed using a percutaneous approach, meaning it involves puncturing the skin to access the inner ear structures. This procedure falls under New Technology Group 11, indicating its experimental or investigational nature.

This code is used when a patient receives an intracochlear infusion of DB-OTO for conditions such as severe to profound sensorineural hearing loss, particularly in clinical trials or specialized treatment protocols. It applies to procedures where the drug is delivered directly into the inner ear fluid spaces via a percutaneous route.

• Ensure documentation clearly specifies "DB-OTO" as the substance infused and "intracochlear" as the infusion site.
• Verify the approach is documented as "percutaneous" and not an open surgical approach.
• Confirm the procedure is performed as part of a New Technology Group 11 protocol, as this is a key component of the code.